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phe pulmonary valve is the most common heart valve
repaired and replaced in the treatment of congenital
eart disease. Valve-bearing extracardiac conduits from the
ulmonary ventricle to the pulmonary artery have allowed
or the surgical treatment of many complex congenital de-
ects. The surgical controversy for reconstruction of the right
entricular outflow tract (RVOT) for the past 30 years has
een primarily focused on which biologic valve to use when
alve insertion is indicated. Replacement of the pulmonary
alve with amechanical valve has recently been advocated for
subset of older children and adults rather than using a
iologic substitute. In the discussion to follow we hope to
onvince the reader that continued use of a biologic pulmo-
ary valve is indicated in all but a handful of older patients
ho require anticoagulation for other reasons.
Aortic and later pulmonary homografts (PH) were the first
alved conduits to be introduced to treat complex congenital
eart disease. Until recently, PH have remained the most
requent choice for RVOT reconstruction in infants and chil-
ren when a conduit was required. At our institution more
han 500 RVOT reconstructions using a valve of various types
ave been performed in children in comparison to 150 aortic
alve replacements, 75 mitral valve replacements, and 15
ricuspid valve replacements. More specifically, the number
f pulmonary valve replacements (PVRs) in children has in-
reased in the last 13 years due to pulmonary autograft re-
lacement of the aortic valve (n  90) as well as the mitral
alve (n 8), employing Ross techniques.1,2 These left heart
alve replacements require a pulmonary valve conduit to
eplace the pulmonary autograft.
During the past 30 years of pulmonary valve replacement
t our institution, only three mechanical valves have been
mplanted in the pulmonary position in adult patients who
lready had other mechanical valves in the aortic or mitral
ositions. The data support our heavy bias against mechani-
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oi:10.1053/j.optechstcvs.2006.08.004al valves in the pulmonary position largely due to the need
or lifelong anticoagulation, risks of thromboemboli, and the
emonstrated durability of xenografts in the tricuspid and
ulmonary positions.
Perhaps the largest series to date evaluating the options
nd outcomes of PVR was published by the Mayo Clinic
roup where late follow-up was reported on 1095 patients
ndergoing biologic conduit placement from the pulmonary
entricle to the pulmonary artery.3 Dearani and colleagues
ery eloquently described not only the impressive extent of
ollow-up (37 years), but also the relative rarity of multiple
e-interventions on the RVOT. More specifically, in their se-
ies which involved 1270 operative interventions, only 306
atients (24%) required one reoperation; 55 patients (4.3%)
equired two reoperations; 6 patients (0.47%) required three
eoperations; and only 3 patients (0.23%) required four re-
perations. This extensive experience confirms that multiple
eoperations in this patient population are infrequent and
hat the use of biologic valves, especially xenografts, have an
xcellent record for durability.
Homograft valve regurgitation, which is often moderate to
evere, develops within 1 year of PH implantation in many
hildren. Regurgitation is rarely an indication for homograft
eplacement in children, although early regurgitation is dis-
ppointing. Obstruction of the PH is themost commonmode
f failure and, as such, replacement is usually required within
years inmost large series of non-Ross PVRs. Our experience
ith PH shows a 10-year survival without re-intervention of
6  7%.4 PHs are even more durable following Ross AVR
ecause the Ross AVR is usually done in older children and
dolescents. The PH used to replace the autograft is placed in
he orthotopic position and can be easily oversized to make
p for the expected shrinkage. The freedom of PH replace-
ent in most large Ross AVR series, including our own, ap-
roaches 95% at 10 years.
Outside the arena of biologic pulmonary valve replace-
ents, transannular pulmonary incisions used to repair Te-
ralogy and ventricular septal defect (VSD) with pulmonary
tresia lend themselves to the insertion of a monocusp pul-
onary valve leaflet under an RVOT patch. We have had
xtensive experience with the Gore-Tex monocusp RVOT
atch (W.L. Gore and Associates, Flagstaff, AZ) pulmonary
alve reconstruction and find this type valve reconstruction
207
208 S. A. Husain and J. BrownFigure 1 Pulmonary arteriotomy.
Biologic versus mechanical valve replacement of the pulmonary valve 209Figure 2 Stay sutures placed to display size of pulmonary valve annulus.Figure 3 Sizing of Gore-Tex monocusp valve based on annulus.
210 S. A. Husain and J. BrownFigure 4 Implantation of Gore-Tex monocusp valve.
Biologic versus mechanical valve replacement of the pulmonary valve 211Figure 5 Gore-Tex monocusp valve following implantation.Figure 6 Gore-Tex closure of pulmonary arteriotomy.
212 S. A. Husain and J. BrownFigure 7 Sequence of implantation technique for Gore-Tex monocusp.
Biologic versus mechanical valve replacement of the pulmonary valve 213Figure 8 Contegra conduit.Figure 9 Contegra bovine jugular vein with valve displayed.
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214 S. A. Husain and J. Brownore durable than a PH in most non-Ross patients. Implan-
ation techniques for the Gore-Tex monocusp RVOT patch
ulmonary valve reconstruction are described (Figs. 1-7).
The more recently introduced Contegra, bovine jugular
enous valved conduit [an Humanitarian Device Exemption
HDE) study device] (Medtronic Inc., Minneapolis, MN),
hows considerable promise as a PVR in infants, small chil-
ren, and in a wide range of older children (Figs. 8, 9). It has
utperformed PH in non-Ross PVR patients at our institu-
ion. It is available in sizes from 12 to 22 mm, does not
equire anticoagulation, does not shrink, and overall retains
alve competence in a high percentage of patients. Seventy
atients have undergone Contegra-valved conduit RVOT re-
onstruction at our institution since 1999. One conduit has
een explanted 2[1\2] years postoperatively because of a RV
seudoaneurysm. Seven patients have required catheter re-
ntervention to relieve stenosis beyond the distal anastomosis
f the conduit to the pulmonary artery bifurcation. In these
atients, the interval to re-intervention was a mean of 11.1
.8 months. The projected price of the Contegra valve is
pproximately one-half that of some PHs in the United States.
ith short-term freedom from dysfunction being similar,
nd the economic advantages presented, the Contegra
alve appears to be an attractive option to PH in PVR and
VOT reconstruction. Longer follow-up studies with a
arge number of patients will be required to see if this
rend continues.5
When comparing the extensive and thorough literature on
iologic options for pulmonary valve replacement, data avail-
ble on outcomes when employing a mechanical conduit or
alve in the pulmonary position are sparse (Table 1). Overall,
lacement of mechanical valves in the pulmonary position
as been reported in fewer than 90 patients with very incon-
istent results.6 Ilbawi and coworkers have published an ex-
erience with 16 mechanical valves in the pulmonary posi-
ion. Six of the 16 (37%) patients developed prosthesis
ysfunction 1 to 6 months after insertion. Actuarial survival
or these patients at 2 years was only 70%.7 Hass and cowork-
able 1 Outcomes of Mechanical Conduits in the Pulmonary
Authors/Country,
Year of Publication
No. of
Patients
Age
(mean) Valve Ty
RO
Rosti/Italy,6 1998 8 10.1 years 6-One-lea
2-Bileaflet
Haas/Netherlands,8
2005
14 24.8 years All bileafle
Dearani/Mayo-US,9
2005
17 Adults ??
ON
Ilbawi/Chicago-US,7
1987
16 ?? All bileafle
Miyamura/Japan,10
1987
5 ?? All bileafle
Fleming/Omaha,11
1987
4 ?? All bileafle
Kiyota/Japan,12
1992
11 ?? All bileaflers have more recently published an experience with 14 me- vhanical valve conduits in the pulmonary position. At fol-
ow-up (11 to 63 months) all but two patients had normal
ight ventricular function with no evidence of valve failure.
ll patients were maintained on aggressive anticoagulation to
chieve an international normalized ratio of 3.0 to 4.5.8 Tilt-
ng disc mechanical valves appear to be less thrombogenic
han their bileaflet counterparts.6
The few publications report small patient populations,
verall short-term follow-up, and a general consensus that
echanical options should only be employed in a highly
elective subset of patients requiring PVR (Table 1). More
pecifically, patients who are of older age, those withmultiple
revious operative interventions associated with complica-
ions, and those with familial support, which is congruent
ith anticoagulation compliance, may form a very small co-
ort of patients in whom this option is advisable.
The complication of cardiac laceration and bleeding from
edo sternotomy can be minimized by closing the pericar-
ium at the first and subsequent sternotomies with Gore-Tex
embrane. The complication of air emboli to the systemic
irculation during PVR can be prevented by electively closing
ll atrial and ventricular shunts.
The controversy over biologic versus mechanical valve
eplacement of the pulmonary valve, even in the case of
multiple interventions” on the RVOT, is unbalanced in
avor of biologic substitutes. Perhaps the most well-pub-
ished proponent of biological options is my opponent in
his debate, Dr. Dearani. Dearani and colleagues’ experi-
nce at the Mayo Clinic as well as that of our institution are
xtensive in quantity of patients and overall good out-
omes in patients with biologic PVR. The misconception
hat the patient population that requires multiple re-inter-
entions (more than two) after initial PVR is large but it is
ess than 5%. The subset of this group who would be
andidates for mechanical PVR would be less than 1 to 2%.
he proven durability PH and xenografts in older children
nd adults and the promising durability of Gore-Tex mo-
ocusp and Contegra conduits outweigh the potential ad-
on
Mortality Thromboembolism Comments
0 No 6.4 years follow-up
0 No 2.9 years follow-up
?? No 8.3 years follow-up
0 No At 2 years 37% had
valve dysfunction
0 2
0 3 At 3.5 years 3
patients were
reoperated on
0 3 3 of 11 patients were
reoperated onPositi
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Biologic versus mechanical valve replacement of the pulmonary valve 215nticoagulation. Mechanical valves in the pulmonary po-
ition should be reserved for adult patients who require
oumadin anticoagulation for other reasons.
eferences
1. Brown JW, Ruzmetov M, Rodefeld MD, et al: Right ventricular outflow
tract reconstruction with an allograft conduit in non-Ross patients: risk
factors for homograft dysfunction and failure. Ann Thorac Surg 80:
655-663, 2005
2. Brown JW, Ruzmetov M, Rodefeld MD, et al: Mitral valve replacement
with Ross II technique: initial experience. Ann Thorac Surg 81:502-
508, 2006
3. Dearani JA, Danielson GK, Puga FJ, et al: Late follow-up of 1095 pa-
tients undergoing operation for complex congenital heart disease uti-
lizing pulmonary ventricle to pulmonary artery conduits. Ann Thorac
Surg 75:399-411, 2003
4. Yemets IM, Williams WG, Webb GD, et al: Pulmonary valve replace-
ment late after repair of Tetralogy of Fallot. Ann Thorac Surg 64:526-
530, 1997
5. Brown JW, Ruzmetov M, Rodefeld MD, et al: Valved bovine jugular
vein conduits for right ventricular outflow tract reconstruction in chil-dren: an attractive alternative to pulmonary homograft. Ann Thorac
Surg 2006 (in press)
6. Rosti L, Murzi B, Colli AM, et al: Pulmonary valve replacement: a role
for mechanical prosthesis? Ann Thorac Surg 65:889-890, 1998
7. Ilbawi MN, Lockhart CG, Idriss FS, et al: Experience with St. Jude
mechanical valve prosthesis in children. A word of caution regarding
right sided placement. J Thorac Cardiovasc Surg 93:73-79, 1987
8. Hass F, Schreiber C, Horer J, et al: Is there a role for mechanical valved
conduits in the pulmonary position? Ann Thorac Surg 79:1662-1668,
2005
9. Dearani JA: Invited commentary. Ann Thorac Surg 79:1667-1668,
2005
0. Miyamura H, Kanazawa H, Hayashi J, et al: Thrombosed St. Jude Med-
ical valve prosthesis in the right side of the heart in patients with
tetralogy of Fallot. J Thorac Cardiovasc Surg 94:148-150, 1987
1. Fleming WH, Sarafian LB, Moulton AL, et al: Valve replacement in the
right side of the heart in children: long-term follow-up. Ann Thorac
Surg 48:404-408, 1989
2. Kiyota Y, Shiroyama T, Akamatsu T, et al: In vitro closing behavior of
the St. Jude Medical heart valve in the pulmonary position: valve in-
competence originating in the prosthesis itself. J Thorac Cardiovasc
Surg 104:779-785, 1992
